A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 7, 2010, Pages 1386-1396

  Schroeder, Rogier P J ^a   Müller, Cristina ^a   Reneman, Suzanne ^a   Melis, Marleen L ^a   Breeman, Wout A P ^a   De Blois, Erik ^a   Bangma, Chris H ^a   Krenning, Eric P ^a   Van Weerden, Wytske M ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biodistribution; Bombesin; Gastrin releasing peptide receptor; Prostatic neoplasms; Radiolabelled analogue; Single positron emission tomography; Targeted imaging

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID PESIN IN 111; AMBA IN 111; DEMOBESIN 1 TC 99M; GASTRIN RELEASING PEPTIDE RECEPTOR; MP 2346 IN 111; MP 2653 IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BOMBESIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; MALE; MOUSE; NONHUMAN; PANCREAS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN TARGETING; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANALOGS AND DERIVATIVES; ANIMAL; COMPARATIVE STUDY; DIAGNOSTIC USE; DRUG STABILITY; FEASIBILITY STUDY; METABOLISM; PROSTATIC NEOPLASMS; QUALITY CONTROL; RADIOGRAPHY; SCINTISCANNING; STAINING; TUMOR CELL LINE;

ANIMALS; AUTORADIOGRAPHY; BOMBESIN; CELL LINE, TUMOR; DRUG STABILITY; FEASIBILITY STUDIES; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; QUALITY CONTROL; STAINING AND LABELING; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77954957077     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1388-2     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
3. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
4. Schröder FH, Denis LJ, Roobol M, Nelen V, Auvinen A, Tammela T, et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003;92 Suppl 2:1-13. (Pubitemid 38091131)
5. el-Gabry EA, Halpern EJ, Strup SE, Gomella LG. Imaging prostate cancer: current and future applications. Oncology (Williston Park) 2001;15:325-36; discussion 339-42.
6. Hricak H, Schöder H, Pucar D, Lis E, Eberhardt SC, Onyebuchi CN, et al. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol 2003;30:616-34.
7. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 2008;60:1-42.
8. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999;59:1152-9.
9. Krenning EP, Teunissen JJ, Valkema R, de Herder WW, de Jong M, Kwekkeboom DJ. Molecular radiotherapy with somatostatin analogs for (neuro-) endocrine tumors. J Endocrinol Invest 2005;28:146-50.
10. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
11. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704-13.
12. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110-22.
13. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111- diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 1997;57:659-71.
14. Maina T, Nock B, Mather S. Targeting prostate cancer with radiolabelled bombesins. Cancer Imaging 2006;6:153-7.
15. Schroeder RP, van Weerden WM, Bangma C, Krenning EP, de Jong M. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods 2009;48:200-4.
16. Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, et al. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu-and 86Y-DOTA-(Pro1, Tyr4)-bombesin (1-14). Bioconjug Chem 2007;18:724-30.
17. de Visser M, Bernard HF, Erion JL, Schmidt MA, Srinivasan A, Waser B, et al. Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours. Eur J Nucl Med Mol Imaging 2007;34:1228-38.
18. Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, Chen J, et al. 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006;47:1144-52.
19. 99mTc]Demobesin-1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 2003;30:247-58.
20. Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007;34:1198-208.
21. Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, et al. Preclinical comparison of (111) In-labeled DTPA-or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 2002;43:1650-6.
22. Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30:917-20.
23. Breeman WA, Fröberg AC, de Blois E, van Gameren A, Melis M, de Jong M, et al. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Nucl Med Biol 2008;35:839-49.
24. Breeman WA, Kwekkeboom DJ, de Blois E, de Jong M, Visser TJ, Krenning EP. Radiolabelled regulatory peptides for imaging and therapy. Anticancer Agents Med Chem 2007;7:345-57.
25. Liu S, Edwards DS, Harris AR, Ziegler MC, Poirier MJ, Ewels BA, et al. Towards developing a non-SnCl2 formulation for RP444, a new radiopharmaceutical for thrombus imaging. J Pharm Sci 2001;90:114-23.
26. Bodei L F M, Nunn J, Llull J, Cremonesi M, Martano L, Laurora G, Scardino E, Tiberini S, Bufi G, Eaton S, de Cobelli O, Paganelli O. 177Lu-AMBA Bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations. European Association of Nuclear Medicine 2007; abstract 463.
27. Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 2006;103:16436-41.
28. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008;49:318-26.
29. Koenig JA, Edwardson JM. Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci 1997;18:276-87.
30. Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, et al. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer 1997;33:1141-8. (Pubitemid 27310789)
31. Milovanovic SR, Radulovic S, Groot K, Schally AV. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160. Prostate 1992;20:269-80.
32. Pinski J, Schally AV, Halmos G, Szepeshazi K. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. Int J Cancer 1993;55:963-7. (Pubitemid 24005342)
33. Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, et al. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate 2000;44:172-80.
34. Stangelberger A, Schally AV, Varga JL, Zarandi M, Szepeshazi K, Armatis P, et al. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clin Cancer Res 2005;11:49-57.
35. Jensen JA, Carroll RE, Benya RV. The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 2001;22:689-99.
36. Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G, Rekasi Z. Peptide analogs in the therapy of prostate cancer. Prostate 2000;45:158-66.